Emcure Pharmaceuticals IPO Details Today : Emcure Pharmaceuticals IPO Details Today is Open on 3 July 2024 and Close on 5 July 2024. Emcure Pharmaceuticals IPO to Raise 19,365,346 shares (Approx ₹1,952.03 Cr) via IPO. The Fresh issue of 7,936,507 shares (Approx ₹800.00 Cr) and The Offer For Sale is 11,428,839 shares of ₹10 (Approx ₹1,152.03 Cr).
We are one of the leading Indian pharmaceutical companies engaged in developing, Manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
We are a research and development (“R&D”) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled us to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada.
We were ranked as Company :-
(i) the 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT September 2023.
(ii) the 4th largest pharmaceutical company by market share in our Covered Markets in terms of Domestic Sales for MAT September 2023.
(iii) the largest pharmaceutical company in the gynecology and human immunodeficiency virus (“HIV”) antivirals therapeutic areas in India in terms of Domestic Sales for MAT September 2023.
Our competitive advantage in the domesti market stems from our differentiated product portfolio, which has allowed us to establish our presence in most of the major therapeutic areas, including gynecology, cardiovascular, vitamins, minerals and nutrients, HIV antivirals, blood-related and oncology/anti-neoplastics.
We are focused towards pharmaceutical products used in chronic (including sub-chronic) therapeutic areas. We have 13 manufacturing facilities across the states of Maharashtra, Gujarat, Sikkim and Karnataka and the union territory of Jammu and Kashmir, in India.
Our facilities are capable of producing pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. Further, our ability to manufacture our own APIs and formulations has allowed us to attain a significant degree of vertical integration, allowing us to source products in a cost-effective manner, ensure quality and security of availability of an essential raw material and protect our intellectual property. In particular, we have in-house manufacturing capabilities for most of our specialty products, including
complex injectables, iron products, photo-chemistry products, chiral molecules and biotherapeutics.
Emcure Pharmaceuticals IPO Date & Price Band Details
| IPO Open Date | 3 July 2024 |
|---|---|
| IPO Close Date | 5 July 2024 |
| IPO Size | 19,365,346 shares (Approx ₹1,952.03 Cr) |
| Fresh Issue | 7,936,507 shares (Approx ₹800.00 Cr) |
| Offer For Sale | 11,428,839 shares of ₹10 (Approx ₹1,152.03 Cr) |
| Lot Size | 14 Shares |
| Face Value | ₹10 Per Equity Share" |
| IPO Price Band | ₹960 to ₹1008 Per Every Share |
| IPO Listing On | BSE & NSE |
| Employee Discount | ₹90 Per Share |
| IPO Retail Quota | 35% |
| IPO QIB Quota | 50% |
| IPO NII Quota | 15% |
| DRHP Draft | Click Here |
| Anchor Investor | Click Here |
Emcure Pharmaceuticals IPO Market Lot Details
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 14 | ₹14,112 |
| Retail Maximum | 14 | 196 | ₹197,568 |
| S-HNI Minimum | 15 | 210 | ₹211,680 |
| S-HNI Maximum | 70 | 980 | ₹987,840 |
| B-HNI Minimum | 71 | 994 | ₹1,001,952 |
Object of the Issue
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by our Company.
- General corporate purposes.
Emcure Pharmaceuticals IPO Allotment & Listings (Details)
| IPO Open Date | 3 July 2024 |
|---|---|
| IPO Close Date | 5 July 2024 |
| Basis of Allotment | 8 July 2024 |
| Refunds | 9 July 2024 |
| Credit to Demat Account | 9 July 2024 |
| IPO Listing Date | 10 July 2024 |
Emcure Pharmaceuticals Financial Reports
| ₹ in Crores | |||
|---|---|---|---|
| Year | Revenue | Networth | PAT |
| 2024 | ₹6715.24 | ₹5978.08 | ₹527.58 |
| 2023 | ₹6031.72 | ₹5278.36 | ₹561.85 |
| 2022 | ₹5918.86 | ₹4946.31 | ₹702.56 |
Our Company Promoters
- Satish Ramanlal Mehta
- Sunil Rajanikant Mehta
Qualitative Factors
1. Well-placed to leverage leading position in the domestic market.
2. Demonstrated capabilities of building brands.
3. Large, diversified and fast-growing product portfolio in international markets.
4. Strong R&D capabilities driving differentiated portfolio of products.
5. Extensive and diversified manufacturing capacity.
6. Highly qualified, experienced and entrepreneurial management team and our Board.
Emcure Pharmaceuticals Comparison Listed Industry Peers Group
| Company Name | Face Value | EPS | PE Ratio | Ro NW (%) | NAV Per | Revenue (₹ in Lakhs) |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Limited | 10.00 | 29.42 | [.] | 21.27% | 138.30 | 59,858.11 |
| Peer Group | ||||||
| Dr. Reddy's Laboratories Limited | 5.00 | 271.47 | 20.45 | 19.36% | 1,398.33 | 246,697.00 |
| Cipla Limited | 2.00 | 34.72 | 34.55 | 11.97% | 290.01 | 227,531.20 |
| Alkem Laboratories Limited | 2.00 | 82.31 | 58.25 | 10.88% | 756.52 | 115,992.60 |
Comparison of accounting ratios with listed industry peers
- Dr. Reddy’s Laboratories Limited
- Cipla Limited
- Alkem Laboratories Limited
Emcure Pharmaceuticals Company Contact Details
Plot No. P-1 & P-2
IT-BT Park, Phase-II
M.I.D.C., Hinjawadi
Pune 411 057
Maharashtra, India
Tel.: + 91 20 3507 0033, + 91 20 3507 0000
E-mail: investors@emcure.com
Website: www.emcure.com
Emcure Pharmaceuticals IPO Registrar
Link Intime India Private Limited
C-101, 1st Floor, 247 Park
Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai 400 083
Maharashtra, India
Tel:+ 91 810811 4949
E-mail: emcure.ipo@linkintime.co.in
Investor grievance e-mail:emcure.ipo@linkintime.co.in
Website:www.linkintime.co.in
4 thoughts on “Emcure Pharmaceuticals IPO details, Date, Price, GMP, Review,”